Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 year, male or female.~* Chronic Heart failure subjects with medical history of cardiac disease or other related cardiovascular disease.~* Left ventricular ejection fraction (LVEF) less than or equal to (=\<) 40 percent (%).~* New York Heart Association (NYHA) class of II - IV~* NYHA II ： Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue or palpitation.~* NYHA III：Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitation.~* NYHA IV：Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort increased.~* Signed Informed Consent Form (ICF).~Exclusion Criteria:~* Acute coronary syndrome (ACS) within 3 months.~* Under beta-blocker treatment for the last 2 weeks.~* Under other medicine treatment which may affect heart rate, like Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine for the last 2 weeks; Under Digoxin treatment \[more than (\>) 0.125 milligram (mg)\].~* Uncontrolled Diabetes \[hemoglobin A1c, (HbA1c) \>7.5%\].~* Severe or uncontrolled hypertension \[resting Systolic Blood Pressure (SBP) \>180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) \>110mmHg at screening period\].~* Severe hypotension \[resting SBP less than (\<) 90mmHg, or resting DBP\<50mmHg\].~* Resting heart rate \<60 beat per minute (bpm).~* Any contradiction to Bisoprolol according to label, including:~* Acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy.~* Cardiogenic shock.~* Atrioventricular block of second or third degree (without a pacemaker).~* Sick sinus syndrome.~* Sinoatrial block.~* Slowed heart rate, causing symptoms (symptomatic bradycardia),~* Decreased blood pressure, causing symptoms (symptomatic hypotension),~* Severe bronchial asthma or severe chronic obstructive pulmonary disease.~* Sever forms of peripheral arterial occlusive disease and Raynaud's syndrome.~* Untreated phaeochromocytoma.~* Metabolic acidosis.~* Hypersensitivity to bisoprolol or to any of the excipients.~* Severe Arrhythmia including atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia.~* Significant valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease.~* Acute pulmonary edema.~* Severe hepatic dysfunction, defined as:~* Serum Alanine Aminotransferase (ALT) \> triple the upper limit of the normal range; and/or~* Serum Aspartate Aminotransferase (AST) \> triple the upper limit of the normal value range and/or~* Severe renal dysfunction, defined as:~* Serum creatinine \> twice the upper limit of the normal range~* Chronic Kidney Disease (glomerular filtration rate \<45 Milliliter per minute).~* Hyperthyroidism or hypothyroidism.~* Severe infectious disease, example (eg) Human Immunodeficiency Virus positive or active tuberculosis.~* Severe autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.~* Severe respiratory, digestive, hematological disease (including Anemia of Hb \< 100 gram per litre) or tumor.~* Known to be hypersensitivity to Bisoprolol, or any of the excipient.~* Substance or alcohol abuse.~* Received heart transplantation or pacemaker implantation; revascularization treatment within 3 months; or plan to receive above treatment in 6 months.~* Currently undertaking other treatment that may affect the safety and/or efficacy evaluation, e.g. beta receptors agonists, et cetera.~* No legal ability or legal ability is limited.~* Subjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent.~* Child-bearing period women without effective contraceptive measures, pregnancy and lactation.~* Participation in another clinical trial within the past 90 days.~* Other significant condition that in the Investigator's opinion would exclude the subject from the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bisoprolol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues